Has Gary Simmons, DO received payments from drug or device companies?

Yes. Drug and device makers reported $82,141 in general payments to Gary Simmons, DO across 63 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Gary Simmons, DO did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Gary Simmons, DO come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Gary Simmons, DO

Hematology & Oncology · Norfolk, VANPI 1770802373

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (49.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Gilead at 51.0% of the total. Among hematology & oncology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$82,141in general payments, 2019–2025

Across 63 payments — averaging $1303.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Gilead$42K
Mckesson Sourcing Services, Inc.$32K
Jazz Pharmaceuticals Inc.$4K
Janssen Scientific Affairs, LLC$3K
Array Biopharma Inc$150
Johnson & Johnson$146
plus $421 from 4 others

$628,648in research payments, 2019–2025

Across 34 payments — averaging $18,490 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Beigene, Ltd.$458K
Beone Medicines Ltd.$52K
Bristol Myers Squibb$48K
AbbVie$36K
Gilead$30K
E.r. Squibb & Sons, L.L.C.$4K
plus $1K from 1 others

What the payments were for

Consulting fees$37,48046%
Speaking & faculty fees$40,84050%
Travel & lodging$2,0282%
Food & beverage$1,7722%
Education$210%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Gilead	26	$41,859
Mckesson Sourcing Services, Inc.	23	$32,292
Jazz Pharmaceuticals Inc.	2	$4,328
Janssen Scientific Affairs, LLC	3	$2,944
Array Biopharma Inc	1	$150
Johnson & Johnson	1	$146
Adaptive Biotechnologies Corporation	2	$132
Takeda Pharmaceuticals U.S.A., Inc.	1	$117
E.r. Squibb & Sons, L.L.C.	2	$89
Rigel Pharmaceuticals, Inc.	2	$84

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Yescarta$35,015
Tecartus$6,560
DEFITELIO$4,240
TECVAYLI$2,940
LORBRENA$150
BRAFTOVI$150
MEKTOVI$150
CARVYKTI$146

How this compares

$82,141 in reported general payments places this provider in the 95th percentile of 293 hematology & oncology providers in Virginia.

See all hematology & oncology providers in Virginia →

Medicare billing

Part B allowed, 2024

$8,918,249

Medicare patients

428

Services billed

176,666

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Lenalidomide	82	$1,125,061
RevlimidLenalidomide	63	$991,970
JakafiRuxolitinib Phosphate	11	$177,466
CalquenceAcalabrutinib Maleate	12	$173,309
EliquisApixaban	38	$33,929
Acyclovir	220	$3,066
Dexamethasone	62	$1,787
Ondansetron Hcl	36	$507
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim	89	$414
Levofloxacin	57	$346
Fluconazole	13	$303
Oxycodone Hcl	13	$260
Olanzapine	18	$235
Prochlorperazine Maleate	13	$215
Ondansetron OdtOndansetron	16	$197

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Norfolk

Michael DansoNorfolk$47K
Nina BalanchivadzeNorfolk$16K
Ruby KochharHampton$236K
Victor YazbeckRichmond$190K
David ChangNewport News$141K
William ErshlerFairfax$139K
Yue ZhangVirginia Beach$105K
Jerome GoldschmidtChristiansburg$105K
Attique SamdaniRichmond$104K
Mark FlemingHampton$71K

See the full list for Virginia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →